Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients as Monotherapy or in Combination With Atorvastatin
Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this placebo-controlled study is to evaluate the low-density
lipoprotein cholesterol (LDL-C) efficacy and dose-response of gemcabene 300, 600 and 900
mg/day administered as monotherapy or in combination with atorvastatin 10, 40, and 80 mg/day
to hypercholesterolemic patients.
Secondary purposes include evaluating the effects of high-sensitivity C-reactive protein
(hsCRP), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) and apolipoprotein
B (ApoB), and safety and efficacy of gemcabene monotherapy and gemcabene/atorvastatin
combination.
Phase:
Phase 2
Details
Lead Sponsor:
Gemphire Therapeutics, Inc. NeuroBo Pharmaceuticals Inc.